US Bancorp DE Buys 4,653 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

US Bancorp DE lifted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 143,424 shares of the company’s stock after buying an additional 4,653 shares during the period. US Bancorp DE’s holdings in Axsome Therapeutics were worth $11,415,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Washington Trust Advisors Inc. bought a new position in Axsome Therapeutics during the fourth quarter worth about $26,000. SG Americas Securities LLC acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $170,000. Neo Ivy Capital Management acquired a new stake in shares of Axsome Therapeutics in the third quarter valued at approximately $204,000. DAVENPORT & Co LLC acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $304,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $308,000. Institutional investors own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Morgan Stanley raised shares of Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $90.00 to $115.00 in a report on Monday, April 29th. UBS Group initiated coverage on shares of Axsome Therapeutics in a report on Tuesday, February 6th. They set a “buy” rating and a $111.00 target price for the company. Truist Financial reaffirmed a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a report on Tuesday, March 26th. Royal Bank of Canada lifted their target price on shares of Axsome Therapeutics from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Finally, Guggenheim lifted their target price on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $121.92.

View Our Latest Stock Report on Axsome Therapeutics

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the sale, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of Axsome Therapeutics stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total value of $2,089,327.20. Following the sale, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The disclosure for this sale can be found here. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Up 1.4 %

AXSM opened at $75.19 on Monday. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40. The firm’s fifty day simple moving average is $74.37 and its 200 day simple moving average is $76.91. The company has a quick ratio of 3.09, a current ratio of 3.20 and a debt-to-equity ratio of 1.25.

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Recommended Stories

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.